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STUDY PROTOCOL Open Access
Rationale and design of SuPPoRT: a multi-
centre randomised controlled trial to
compare three treatments: cervical
cerclage, cervical pessary and vaginal
progesterone, for the prevention of
preterm birth in women who develop a
short cervix
Natasha L. Hezelgrave, Helena A. Watson, Alexandra Ridout, Falak Diab, Paul T Seed, Evonne Chin-Smith,
Rachel M. Tribe* and Andrew H. Shennan
Abstract
Background: Clinically, once a woman has been identified as being at risk of spontaneous preterm birth (sPTB) due
to a short cervical length, a decision regarding prophylactic treatment must be made. Three interventions have the
potential to improve outcomes: cervical cerclage (stitch), vaginal progesterone and cervical pessary. Each has been
shown to have similar benefit in reduction of sPTB, but there have been no randomised control trials (RCTs) to
compare them.
Methods: This open label multi-centre UK RCT trial, will evaluate whether the three interventions are equally efficacious to
prevent premature birth in women who develop a short cervix (<25 mm on transvaginal ultrasound). Participants will be
asymptomatic and between 14+0 and 23+6 weeks’ gestation in singleton pregnancies. Eligible women will be randomised
to cervical cerclage, Arabin pessary or vaginal progesterone (200 mg once daily) (n= 170 women per group).
The obstetric endpoints are premature birth rate <37 weeks’ of gestation (primary), 34 weeks and 30 weeks (secondary
outcomes) and short-term neonatal outcomes (a composite of death and major morbidity). It will also explore whether
intervention success can be predicted by pre-intervention biomarker status.
Discussion: Preterm birth is the leading cause of perinatal morbidity and mortality and a short cervix is a useful way of
identifying those most at risk. However, best management of these women has presented a clinical conundrum for
decades.
Given the promise offered by cerclage, Arabin pessary and vaginal progesterone for prevention of preterm birth in
individual trials, direct comparison of these prophylactic interventions is now essential to establish whether one treatment
is superior. If, as we hypothesise, the three interventions are equally efficacious, this study will empower women to make a
choice of treatments based on personal preference and quality of life issues also explored by the study.
(Continued on next page)
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Our exploratory analysis into whether the response to intervention is related to the pre-intervention biomarker status
further our understanding of the pathophysiology of spontaneous preterm birth and help focus future research questions.
Trial registration: EudraCT Number: 2015-000456-15. Registered 11th March 2015
Keywords: Preterm birth, Arabin pessary, Cerclage, Progesterone, Cervical length, Biomarkers
Background, including rationale and previous
systematic reviews
There are 12.9 million premature births annually worldwide
[1] and despite the magnitude of the problem, there is no
established early pregnancy screening test or effective treat-
ment for women once a high risk of spontaneous preterm
birth (sPTB) is ascertained. The associated morbidity, mor-
tality and high health costs are well documented. Only 39%
of those infants born <26 weeks’ gestation survive and 13%
of these suffer severe cerebral palsy or sensory impairment
[2]. Despite considerable efforts to introduce new therapies
for the prevention and treatment of spontaneous preterm
labour, sPTB rates are still rising; 6% of births in the UK are
premature. sPTB is thought to be the result of multiple aeti-
ologies influenced by a wide number of genetic, biological,
psychosocial and environmental factors (e.g. multiple preg-
nancy, infection, placental abruption and stress) yet the
chronology and aetiology of sPTB is insufficiently
understood. Early sPTB likely results from a complex inter-
action of maternal and/or fetal inflammatory responses that
culminate in progressive cervical shortening and myometrial
contractions.
Detection of a short cervix using transvaginal ultrason-
ography has emerged as a useful predictor of sPTB in
both low and high risk pregnancies [3, 4] and risk of pre-
term birth is inversely related to cervical length; the
shorter the cervix, the higher the risk of preterm birth.
In clinical practice, once a woman has been identified as
being at higher risk of sPTB by virtue of a short cervix, a
decision regarding prophylactic treatment must be
made. Three interventions have been proposed to treat
patients with a short cervix; cervical cerclage [5, 6], cer-
vical pessary [7] or vaginal progesterone therapy [8–10].
There is little evidence to guide clinicians as to which of
these three interventions is the best to use and so the
treatment received predominantly depends on the centre
a woman is treated in and her clinician’s preference.
A cerclage is the insertion of a ‘purse string’ suture
around the cervix under regional anaesthesia. There is
little consensus on the optimal procedure or technique
(e.g. low/high vaginal, abdominal, tape/nylon, single/
multiple, endocervical/purse string) or timing of inser-
tion (elective, ultrasound indicated, pre-conceptual).
Furthermore, the mechanism of action is not under-
stood; cerclage may offer a degree of structural support,
but also plays a role in maintaining a biochemical barrier
protecting membranes against exposure to ascending
pathogens. It also is known to induce an inflammatory
response, which may encourage tissue repair. A ‘history
indicated’ cerclage is inserted in early pregnancy (8–14
weeks’) in women who have a history of late miscarriage
or preterm birth. The largest randomised controlled trial
comparing history-indicated cerclage with expectant
management (n = 1292), demonstrated that benefit of
cerclage was only seen in women with three prior fetal
losses/premature deliveries, where their risk of preterm
birth reduced by more than half [6].
‘The benefit of cerclage following confirmation of
cervical shortening (ultrasound indicated cerclage), has
been reported in a subgroup of high risk women (history
of preterm second-trimester loss or birth before 36 weeks
of gestation) who have a cervix <25 mm in length, with
meta-analysis [5] demonstrating a significant reduction
in delivery before 35 weeks of gestation [relative risk
(RR) 0.57; 95% confidence interval (CI) 0.33–0.99] for
women with prior second trimester miscarriage, and RR
0.61; 95% CI 0.40–0.92 for women with prior preterm
birth] when compared with expectant management.’
The Arabin pessary is a round and cone shaped flexible
silicon device which is designed to be inserted into the va-
gina and sit in the upper fornix, to support and incline the
cervix, with the intention to prevent premature cervical
shortening and preterm birth. Goya et al. [7], [11] re-
ported a multicentre randomised controlled trial (n = 385)
on pessary use in unselected women screened by transva-
ginal ultrasound (TVS) and showed that in women with a
short cervical length (<25 mm) between 18 and 22 weeks,
the pessary reduced the rate of sPTB <34 weeks’ gestation
compared with controls (6% vs 27%, odds ratio 0 · 18,
95% CI 0 · 08 to 0 · 37; p < 0 · 0001), with a significant dif-
ference detected in the occurrence of composite poor neo-
natal outcome. In a subsequent smaller RCT, 108 Asian
women with a singleton pregnancy and a cervical length
<25 mm at routine second-trimester TVS were random-
ized to either pessary or control group. The mean gesta-
tional age at delivery was 38.1 weeks in the pessary group
compared with 37.8 weeks in the expectant management
group, with no significant differences in the rates of deliv-
ery before 28, 34 or 37 weeks [12].
Vaginal progesterone is given as a potential therapy to
sPTB in singleton pregnancies based on a Cochrane system-
atic review [8] reporting that prophylactic progesterone
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(intramuscular and vaginal administration of varying doses)
was associated with a significant reduction in preterm
birth <34 weeks (one study; 142 women; RR 0.15;
95% CI 0.04–0.64) and preterm birth at less than
37 weeks (four studies; 1255 women; RR 0.80; 95%
CI 0.70–0.92). A meta-analysis of vaginal progester-
one treatment given to all women with a short cervix
<25 mm showed a reduction in preterm birth at
<33 weeks; [RR, 0.58; 95% confidence interval [CI],
0.42 to 0.80), <35 weeks (RR, 0.69; 95% CI, 0.55 to
0.88), and <28 weeks (RR, 0.50; 95% CI, 0.30 to
0.81) and neonatal composite morbidity and mortality
(RR 0.57; 95% CI, 0.40 – 0.81) [9]. A recent large
study suggested a lack of efficacy of vaginal progester-
one and no long-term benefit at two years, adding to
the uncertainty around progesterone use [10].
The plasma (and/or uterine) concentration of proges-
terone required to reduce sPTB is unknown, and the
mechanism of action uncertain. It is, however, frequently
used in clinical practice (usual dose 200–400 mg). The
doses of vaginal progesterone used in completed trials
are 100 mg (n = 142) or 200 mg (n = 250) [13]. Whilst
vaginal progesterone use for the prevention of sPTB is
unlicensed, it is commonly used in clinical practice in
the UK and Europe and is also recommended for use in
the USA by the Society for Maternal and Fetal Medicine.
NICE recommends vaginal progesterone in women be-
tween 16+0 and 24+0 weeks with a cervical length
<25 mm and no history of late miscarriage or sPTB.
Progesterone or cerclage are advised by NICE for
women with a history of late miscarriage or preterm
birth [14]. Currently cervical cerclage is the Royal Col-
lege of Obstetricians (RCOG) recommended treatment
for women with a short cervix <25 mm and a history of
1 or more late miscarriages or preterm birth [15].
However, there have been no direct comparison of
these three interventions to inform guidelines as to the
optimal management of all high risk women who de-
velop a sonographic short cervix. Women at high risk of
sPTB with a short cervix cannot, at present, be coun-
selled as to which is the most suitable intervention to re-
duce their risk of delivering prematurely.
Our research group recently published an exploratory
observational study [16] to evaluate the relationship be-
tween pro-inflammatory cytokines, cervical shortening
and intervention, within which 37 women who developed
a short cervix were randomised to treatment with vaginal
progesterone (n = 17) or cervical cerclage (n = 19). A clin-
ically important trend towards benefit (gestation at deliv-
ery) was noted in the cerclage group (mean gestation
33.7 weeks’ cerclage versus 31.5 weeks’ progesterone) al-
though this result did not achieve statistical significance.
Alfirevic et al., [17] retrospectively compared three co-
horts of women with previous sPTB <34 weeks and
short cervix treated with cerclage (n = 142), vaginal pro-
gesterone (n = 59) or a pessary (n = 42). There were no
significant differences in rates of perinatal loss, neonatal
morbidity or sPTB, apart from a higher rate of sPTB be-
fore 34 weeks’ gestation in the vaginal progesterone vs
pessary groups. It was concluded that randomized com-
parisons of these three management strategies, or com-
binations thereof, are needed to determine optimal
management. If a randomised study, such as the one de-
scribed here, showed that the three treatments were
equally efficacious, then women and clinicians would
have greater choice regarding treatment plans, expensive
surgery (and potential complications) could be avoided.
The pessary could be inserted at a later gestational age,
when cerclage is no longer performed, potentially in an
outpatient setting.
This randomised controlled trial will answer the
current clinical dilemma of which is the most effective
method to treat women at high risk of sPTB who
develop a short cervix.
Hypothesis
Current treatments for ultrasound indicated cervical
shortening in women at risk of preterm birth confer
equal benefit in terms of reducing the numbers of births
<37 weeks of gestation.
Aim
In a randomised controlled trial, to compare three
evidence-based treatments for a short cervix detected by
ultrasound scan in women at high risk of premature
birth: cervical cerclage, cervical pessary and vaginal pro-
gesterone therapy.
Objectives
Primary objectives
1. To determine if treatment with cervical cerclage,
cervical pessary or vaginal progesterone in women
at high risk of preterm birth who develop a short
cervix by ultrasound measurement are equally
efficacious to improve obstetric outcome by
lengthening pregnancy and reducing the incidence
of preterm delivery before 34 weeks’ gestation.
2. To evaluate the impact of the interventions on
short-term neonatal outcomes, assessed as a
composite of perinatal death (within 28 days) and
major morbidity.
Secondary objectives
3. To undertake an exploratory analysis to determine
whether the response to intervention for a short
cervix is related to the pre-intervention
inflammatory biomarker status (cervicovaginal
fluid (CVF), blood).
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4. To evaluate the acceptability to women and
clinicians of each of the three treatment arms.
5. To assess the impact of management strategies on
health economic outcomes for mother and infant in
terms of number of nights in each hospital setting;
cost data to hospital discharge/28 days postnatal (it
is anticipated that a 6 month and 2 year follow up
may be performed if funding is obtained).
Centres
As a National Institute for Health Research registered
portfolio study, SuPPoRT is open to UK hospitals with
the appropriate facilities and experience of preterm birth
surveillance and treatment.
Design
An open label, multi-centre three armed randomised con-
trolled trial, with an embedded biomarker study, to explore
three treatments (cerclage, cervical pessary and vaginal pro-
gesterone) for a short cervix in pregnancy (Figure 1).
Women who develop a short cervix will be rando-
mised to one of 3 treatments: cervical cerclage (proced-
ure to take place within 7 days of diagnosis, removed at
37 weeks’), cervical pessary (inserted at diagnosis and re-
moved at 37 weeks’), vaginal progesterone (200 mg once
daily per vagina until 34 weeks’ gestation from time of
randomisation). At an appropriate time-point between
time of randomisation and time of intervention, women
will provide a CVF sample and blood sample (for
biomarker analysis, optional, if facilities allow).
These will be repeated every approximately every two
weeks according to routine clinic visits thereafter until
28 weeks’ gestation.
Eligibility and exclusion criteria
Eligibility criteria
High risk women with singleton pregnancies who are
found to have cervical length <25 mm on transvaginal
ultrasound between 14+0 weeks’ gestation (dated by
ultrasound or last menstrual period and adjusted for
ultrasound estimated date of delivery once ultrasound
performed if no miscarriage prior to dating ultrasound)
until 23+6 weeks’ gestation with written consent to par-
ticipate and one or more of the following risk factors;
 History of
o Previous preterm premature rupture of the fetal
membranes (≤37 weeks’)
oHistory of previous sPTB/second trimester loss
(≥16 weeks’ or ≤ 37 weeks’ gestation).
oAny cervical procedure to treat abnormal smears
i.e. large loop excision, laser conisation, cold
knife conisation or radical diathermy.
Women with an incidental finding of a short cervix on
ultrasound scan (e.g. at the time of anomaly scan) are
also eligible for inclusion in the study.
Exclusion criteria
 Women with persistent fresh vaginal bleeding
evident on speculum examination.
 Women with visible membranes evident on speculum
examination or open cervix on ultrasound scan.
 Women with severe abdominal pain/evidence of
sepsis (as judged by attending clinician).
 Known significant congenital or structural or
chromosomal fetal abnormality.
 Suspected or proven rupture of the fetal membranes
at the time of recruitment.
 Women currently using progesterone pessaries or who
have taken progesterone beyond 18 weeks gestation.
 Women who have a cervical suture in situ (vaginal
or abdominal).
 Women who already have a cervical pessary in situ.
 If the attending clinician feels that an individual
woman is more suited to one treatment modality
over another.
 Insufficient understanding of the trial in the opinion
of the Investigator.
 Any contraindications or cautions to the
investigational medicinal product including:
known allergy or hypersensitivity to progesterone,
hepatic dysfunction, undiagnosed vaginal bleeding,
mammary or genital tract carcinoma,
thrombophlebitis, thromboembolic disorders,
cerebral haemorrhage or porphyria.
Concomitant medication
Participants will be permitted to use any concomitant
medication (aside from the other study products them-
selves) required alongside the study drug/procedure/de-
vice. They will be enquired about and recorded at every
visit. Any other medication or treatment that would
form normal clinical management for these women at
risk of preterm labour, i.e. antibiotics, corticosteroids,
tocolytics, etc. will be permitted according to local
hospital guidelines and clinician preference.
Methods
Recruitment: Identification and consent of participants
Women will be recruited from hospital centres that
perform transvaginal ultrasound cervical length meas-
urement routinely for women at high risk of preterm
birth. High risk pregnant women who are found to
have a cervical length of <25 mm (lowest of 3 mea-
surements) during attendance at high risk surveillance
antenatal clinic (hereafter referred to as prematurity
surveillance clinic) will be identified. Their case notes
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will be reviewed for the patient’s potential recruitment
into the trial and eligible patients will be informed of the
study at time of diagnosis of short cervix. Members of the
research team (midwives, doctors and scanning practi-
tioners) will be familiar with the study so can discuss the
research with women when required.
Fig. 1 Flow chart of participants in the trial
Hezelgrave et al. BMC Pregnancy and Childbirth  (2016) 16:358 Page 5 of 10
All participants will be provided with a written patient
information leaflet with verbal translation available for
non-English speaking women (via Language Line where
available). Women will be consented by an appropriately
trained (Good Clinical Practice) doctor. Women will be
given information about the study and will be allowed
adequate time (up to 48 hours, depending on length of
cervix and urgency of treatment, as determined by the at-
tending clinician) to read the patient information sheet
and provide written informed consent. If a participant
does not consent to sample collection (CVF, saliva, blood),
or if the study site does not have the facilities to collect
and process samples, this does not preclude trial entry.
Randomisation
Once written informed consent has been given, the par-
ticipant will be randomly assigned (1:1:1) to cerclage,
progesterone or pessary. Randomisation will be carried
out online via the Medscinet web portal (www.medsci-
net.net). Users will be assigned a personal identifier
number. Due to the nature of the interventions, the
study is not blinded to the clinician or patient but re-
cruiters and trial coordinators will not have access to the
randomisation sequence. Women will be informed at
time of recruitment to which arm they have been
randomised. A ‘minimisation’ procedure, using a
computer-based algorithm, will be used to avoid chance
imbalances in important stratification variables. Stratifi-
cation variables will be a) gestation, b) BMI <30 or >30
kg/m2) risk factor (previous premature delivery
<24 weeks & previous cervical surgery). Medscinet will
write the randomisation program and hold the allocation
code. Contact information will be obtained from the patient.
Demographic measures will be entered into the central trial
database. Following randomisation, the obstetrician will then
arrange for the intervention to be performed as the random-
isation indicates. There is no ‘emergency code break’ pro-
cedure as the trial is an open label RCT.
Intervention (14 + 0-23 + 6 weeks’ gestation)
Cervical cerclage
The cerclage procedure will be booked at the time of ran-
domisation. It will be performed (according to local prac-
tice and procedures) within 7 days of recruitment to the
trial. A vaginal cerclage will be inserted in the operating
theatre by a clinician trained in the procedure, according
to the technique preferred by the clinician. It is usually
inserted under regional anaesthetic. Tocolysis, antibiotics
and antenatal corticosteroids can be considered at the cli-
nician’s preference, but will be documented and consid-
ered in the analysis. The patient will usually go home the
same day. The suture can be removed easily by exposing
the cervix and cutting the knot, usually without the need
for anaesthetic. This will be done electively when a woman
is 37 weeks’ gestation, or if she presents in symptomatic
preterm labour before labour becomes established, to
avoid cervical trauma. The suture will also be removed if
there is clinical evidence of chorioamnionitis.
Vaginal progesterone
Vaginal progesterone (200 mg once daily) will be pre-
scribed at the time of randomisation. Patients will be
shown how to insert one progesterone pessary every day
until 34 weeks’ gestation (or delivery, whichever is soon-
est). If the cervix shortens and membranes are visible,
prior to 24 weeks’ gestation, a rescue cerclage will be
inserted, according to local protocols.
Dose changes
No dosage adjustments are permitted. Women recruited
will be at high risk of early delivery and therefore likely
to be highly motivated to comply with treatment. We
will monitor compliance carefully by asking local staff to
review medication packs. Patients will be asked to return
any unused medication at a 34 weeks’ visit (or after de-
livery) whichever is soonest, and this will be recorded in
the online database. If progesterone has been stopped
for reasons other than those listed above it can be
restarted at any time up to 34 weeks of gestation.
Cervical pessary
The appropriately sized pessary will be inserted within
7 days of randomisation by the attending clinician, who
will be trained in the procedure. They will be given de-
tailed written instructions about its subsequent manage-
ment. It will be removed by a trained clinician at
37 weeks’ gestation (or in the event of established
labour). If the cervix shortens and membranes become
visible prior to 24 weeks’ gestation, a rescue cerclage will
be inserted, according to local protocols.
Study assessments
A summary of study visits is given in Table 1.
Pre-intervention biomarker measurement
Women will provide biological samples at a convenient
time between randomisation and intervention in order
to obtain biomarker levels (if study site facilities allow
and women consent). This will include one sterile
speculum examination and approximately 4 cervico-
vaginal swabs (high vaginal and/or endocervical), a swab
to measure quantitative fetal fibronectin (qfFN) will be
performed from 18 weeks’ gestation, and two 15 ml
blood samples, one for genetic analysis; one for bio-
marker analysis. These samples will be repeated at each
subsequent routine clinic visit until 28 weeks’ gestation.
Sample collection is not mandatory for trial participa-
tion. Some women may only want to provide samples at
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a single visit or only provide one or more of the samples
listed.
Subsequent study visits
All participants will be seen in a follow up appointment,
normally between 2 and 4 weeks post-intervention. Subse-
quently, all follow up visits will be at the discretion of the at-
tending clinician. Each visit will be documented on the
online database. A TVS cervical length measurement should
be performed, and results recorded on the trial database, at
each visit. At each visit, information will be obtained on
compliance, adverse events or pregnancy complications.
The final study visit will take place between 34+0 and 38+0
weeks’ gestation. Patients randomised to progesterone will
be asked to return all unused medication and empty blister
packs, in order to collect compliance information. Patients
randomised to pessary will return at 37 weeks for removal.
Patients randomised to cerclage will be seen between 34
and 37 weeks, and an appointment made for removal in the
appropriate clinical area. If delivery has occurred prior to
this time, then study staff will contact the participants, to ar-
range a follow up visit and collection of unused medication.
Other than the baseline post intervention visit and final
study visit, all other trial visits will be timed to routine clinic
attendances according to local clinical protocols and clin-
ician practice. Interim study data will therefore only be col-
lected if the patient attends the appropriate department for
routine purposes. Note review will take place 28 days after
delivery to capture postnatal maternal, fetal and health eco-
nomic data.
Linkage of data
At the time of recruitment a unique study number will
be allocated to the patient. Data will be recorded on a
password protected KCL computer in order that recruits
can be contacted and delivery outcomes recorded. The
anonymised research record will not contain any patient
identifiable data. All records will be anonymised at time of
data entry in accordance with the Data Protection Act 1998.
Women will be followed up until postnatal discharge. Paper
copies of consent forms will be stored separately and
numerically (by study ID) and kept in a secure location in
accordance to the Data Protection act 1998.
Withdrawal from study
Participation in the study is voluntary. A patient has the
right to discontinue drug/pessary or completely with-
draw from the study at any time, for any reason. Identifi-
able data or tissue already collected with consent will be
retained and used in the study with the women’s permis-
sion. Consent would be sought to collect participant’s
delivery details (if delivery has not yet occurred). If the
participant is withdrawn due to a serious adverse event,
the Principal Investigator will arrange for follow-up visits
or telephone calls until the event has resolved or stabi-
lised. However as the participants are pregnant women
outcome data will be collected routinely (i.e. until
delivery) and used in the analysis unless the consent is
specifically refused by the participant.
Expected duration of the trial
The end of the trial will be defined as 28 days post-
delivery or discharge from hospital (whichever sooner)
of the last recruited participant and infant. At least three
centres will be involved, each receiving referrals from
satellite units, and will recruit over a 36 month period.
Outcomes
Primary Endpoint
Delivery < 37 completed weeks’ gestation (powered).
Table 1 Summary of study visits
Procedure Screening &
randomisation
14+0-23+6 weeks
gestation
Intervention
(day 0)
14+0-23+6
weeks gestation
Baseline visit (day)
1–4 weeks after
procedure
Follow up visits
(if clinically
indicated)
Final visit
34+0-38+6
weeks’ gestation
Note review
(no visit required)
Visit window (± days) −7 to 0 days Day 0 7-28 days Approximately
2–4 weekly
3 Discharge from
Hospital or 28 days
postnatal
Informed consent ✓
Medical history and concomitant
medications
✓ ✓ Optional ✓
Transvaginal ultrasound Scan ✓ ✓ Optional
Biological sample collection Optional Optional Optional
Adverse events (AEs) changes to
interventions
✓ As needed ✓ ✓
Count of un-used medication ✓
Pessary/Cerclage removal ✓
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Secondary endpoints
 Adverse perinatal outcome, defined as a composite
outcome of death (antepartum/intrapartum
stillbirths plus neonatal deaths prior to discharge
from neonatal services) or one (or more) of
intraventricular haemorrhage, periventricular
leukomalacia, hypoxic ischemic encephalopathy,
necrotizing enterocolitis, bronchopulmonary
dysplasia and sepsis.
 Delivery <30 & 34 completed weeks’ gestation.
 Gestation at delivery.
 Time between intervention and delivery.
 Requirement for rescue cerclage (bulging fetal
membranes).
 Other maternal and fetal outcomes: clinical course,
therapies administered, maternal and fetal morbidity
and mortality data until discharge or 28 days postnatal
(whichever soonest), adverse effects related to
intervention.
 Participant and clinician’s perception of treatment/
satisfaction: questionnaires with a selection of
participants at 0–2 weeks post procedure.
Questionnaires at one year are planned if funding is
obtained.
 Health costs at 28 days postnatal.
 Biochemical end-points (on available samples):
cervicovaginal swabs will be taken to determine the
presence of infection and concentrations of biomarkers
of preterm birth, infection and inflammation, and blood
samples taken for inflammatory markers and genetic
analysis. Results will be correlated with maternal and
fetal outcomes.
Statistical analysis plan including sample size and power
calculations
Our previous experience (captured by a robust database of
outcome data from >2000 women attending our prematur-
ity clinic) indicates that approximately 50% of women with
short cervices (<25 mm) treated with cerclage) deliver early
(<37 weeks). From existing published evidence, we have
good reason to believe that cerclage, vaginal progesterone
and silicone Arabin pessary are all of approximately equal
efficacy and reduce the rate of prematurity in women from
75% (untreated) to around 50% [6, 7, 9, 17]. We therefore
determine to confirm this by a 3-arm equivalence study.
Equivalence is defined as agreement to within 20% (e.g.
40% to 60%). In accordance with Jones et al. [18], we allow
for differences in both directions in calculating the power.
Complete data on 170 women per arm (510 in all) will give
us 90% power to detect clinically important differences of
20% or more in either direction. To allow for dropouts, we
aim to recruit 540 women in total.
Analysis will be according to intention to treat. The
main outcome is delivery before 37 weeks'. Results will
be presented as both odds ratios and risk differences,
leading to number needed to treat (NNT) if appropriate,
according to CONSORT guidelines. Given that high risk
women with a history of invasive cervical surgery, and
those with incidental findings of a short cervix may have
a different pathophysiology to those women with a his-
tory of preterm birth, sub-group analysis will be per-
formed according to risk factor. As we are powering for
equivalence in the maternal outcome, it is not antici-
pated that the neonatal outcomes will be different how-
ever we will collect data on composite neonatal end
point (not specifically powered for equivalence).
For biomarker analysis, results will be analysed at each
time point in a cross sectional analysis, and on a case–
control basis. We will express the overall usefulness of
each marker for prediction of the primary outcome as a
ROC area (receiver operating characteristic), with 95%
confidence interval and p-value. We will describe the
performance of the most useful markers in terms of
sensitivity, specificity and related measures for selected
cut-points. We will use logistic regression in order to
identify possible useful combinations of markers; where
possible, we will use the repeated measurements to de-
scribe the change in test performance with gestation.
Side effects and adverse events reporting
Study participants are advised to contact the chief inves-
tigator or research team at any time if symptoms de-
velop. Expected SAEs are those events which are
expected in the patient population or as a result of the
routine care/treatment of a patient. The trial interven-
tions are those which would be routinely offered in clin-
ical practice. Cervical cerclage insertion is an established
surgical procedure, which is associated with minimal
risks. These include infection, miscarriage, bleeding, rup-
ture of membranes and difficulty with suture removal.
The cervical pessary is not associated with known risk.
There is a risk of allergy with vaginal progesterone.
Symptoms of overdose may include somnolence, dizzi-
ness, euphoria or dysmenorrhoea (latter not applicable
for pregnant women). Treatment is largely observation
with symptomatic and supportive measures as necessary.
Serious adverse events/reactions which are unrelated
to these clinical procedures will be reported as SAEs.
Events that are primary or secondary outcome mea-
sures are not considered to be SAEs and will be reported
in the normal way, on the appropriate electronic case re-
port form. These include:
Maternal: Premature labour, premature rupture of mem-
branes, chorioamnionitis
Infant: Perinatal death (unless unexpected in this popu-
lation), low birth weight, requirement for supplemental
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oxygen or ventilation support, complications of prematur-
ity (e.g. intraventricular haemorrhage, necrotising entero-
colitis, encephalopathy, seizures, hypoglycaemia) unless
unexpected in this population
In addition, the following common pregnancy complica-
tion events will not be considered SAEs: hospitalisation
for pre-eclampsia or pregnancy induced hypertension,
hospitalisation for symptoms of preterm labour (e.g. rup-
ture of membranes, vaginal bleeding); hospitalisation for
maternal discomfort; hospitalisation for rest; hospitalisa-
tion for observation or monitoring for a period of less
than 12 hrs; delivery complications such as caesarean
section of postpartum haemorrhage.
Interim analysis and treatment stopping rules
There is no planned interim analysis. The trial may be pre-
maturely discontinued by the Sponsor, Chief Investigator or
Regulatory Authority on the basis of new safety information
or for other reasons given by the DMEC/TSC regulatory au-
thority or ethics committee concerned. If the trial is prema-
turely discontinued, active participants will be informed and
no further participant data will be collected.
Protocol guidelines
All SPIRIT guidelines were adhered to in the creation of
this protocol.
Committee oversights
An independent Trial Steering Committee and an inde-
pendent Data Monitoring Committee has been appointed
to oversee trial management and safety of the participants
in the trial.
Discussion
Preterm birth is the leading cause of perinatal morbidity
and mortality and a short cervix is a useful way of iden-
tifying those most at risk. However, best management of
these women has presented a clinical conundrum for
decades.
Given the promise offered by cerclage, Arabin pessary
and vaginal progesterone for prevention of preterm birth
in individual trials, direct comparison of these prophy-
lactic interventions is now essential to establish whether
one treatment is superior. If, as we hypothesise, the
three interventions are equally efficacious, this study will
empower women to make a choice of treatments based
on personal preference and quality of life issues also ex-
plored by the study.
We know that the aetiologies of preterm birth are di-
verse. Whilst pragmatic, the study of this heterogenous
group together may be artificial and responsible for con-
flicting results from previous studies. Our exploratory
analysis into whether the response to intervention is re-
lated to the pre-intervention biomarker status may help us
identify subgroups of women who respond differently to
each treatment. This will enable more targeted treatments
for high risk women in the future. It will also further our
understanding of the pathophysiology of spontaneous pre-
term birth and help focus future research questions.
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